Prowess in the synthesis and delivery of therapeutics and diagnostics is a hallmark of the Chemistry of Life Processes Institute (CLP) that reflects its origins in the discovery of Lyrica® by Dr. Richard Silverman. CLP is committed to harnessing the power of transdisciplinary research among fields such as life sciences, physical sciences, engineering, and medicine to translate research into the marketplace where it can exert a profound beneficial impact on human health. CLP transdisciplinary scientists understand that interactions with the business world are critical if a new discovery is going to make it out of the lab and into the world where it can help people.
William Sargent, PhD, provides mentoring in the drug development process, from initiation to FDA marketing approval, to interested researchers across campus looking to explore commercialization.
Sargent is available on both the Chicago and Evanston campuses to consult with faculty, students and staff interested in developing potential therapies emerging from their translational research.
Consultation appointments made be made via email at firstname.lastname@example.org .
Central to this process will be his assistance in the creation of a Target Product Profile (TPP) for compounds under development. The Profile will enable the entrepreneur to start therapeutic development process with the end in mind. “The TPP is most helpful early on in development, as it sets the road map for achieving the IND and provides a long-term view of what data will be needed to validate claims in the final package insert,” said Sargent. “It’s also a great tool to form the basis of a value proposition and for later interaction with the FDA.”
Dr. Sargent has over 30 years in the pharmaceutical industry, preceded by 10 years as an independent researcher in academia. Sargent is well-versed in the therapeutic development emerging from local universities, having served as member of the Chicago Innovation Mentors (CIM) program since 2013. Previously, he held senior positions at Pfizer, Hoechst-Roussell Pharmaceuticals, Lorex Pharmaceuticals, Searle, and Pharmacia. As President and General Manager of Lorex, he oversaw FDA approval for direct to consumer advertising for the lead product Ambien. He led the International launch of Sutent® for renal cell carcinoma and gastrointestinal stromal cancer while Senior Medical Director and Team Leader for the anti-angiogenic portfolio at Pfizer. Dr. Sargent received a PhD in physiology from the University of Tennessee Center for the Health Sciences where he remained as faculty in Physiology and Biophysics for approximately 10 years.
Faculty Entrepreneurship: Moving Discoveries Into Society
CLP founding director Thomas V. O’Halloran (chemistry and molecular biosciences) studies the assembly and characterization of molecules that alter the regulatory biology of transition metal receptors involved in signaling and trafficking pathways.
His discoveries have been commercialized to treat triple negative breast cancer, Wilson disease, infectious diseases, and fungal infections.
He has co-founded multiple biotech start-up companies including Tactic Pharma, Valence Therapeutics, and Viamet Pharmaceuticals.
Companies Founded by CLP Faculty
Founder: Olga Volpert
Co-Founder: Jack Henkin
Founder: Thomas O’Halloran
Co-Founder: Chandler Robinson
Founder: Richard Silverman
Co-Founders: Dmitri Krainc
Founder: Jack Henkin
Co-Founders: Andrew Mazar, Olga Volpert
Northwestern Partners in Entrepreneurship
Basic Science Discoveries Translated into Healthcare
Treating severe brain injury often requires immediate surgery, including implantation of an electronic sensor that monitors tissues and fluids and digitally provides real-time information about intracranial pressure, temperature and wound healing. These devices,...
Watching neurons die provides Richard Morimoto with clues on how he might better keep them alive. The molecular biologist specifically studies neurons exposed to cell stress as well as those expressing proteins linked to neurodegenerative diseases.Now, a new...
For years, drug developers have tried, but failed, to build the perfect biological Trojan horse. Now, a new approach that disguises chemotherapeutic drugs as fat stands to outsmart, penetrate and destroy tumors. For the first time, a team of Northwestern researchers,...